Cannabis
DemeRx Inc. to Present at Wonderland Miami by Microdose
Florida–(Newsfile Corp. – November 6, 2021) – DemeRx IB, Inc. (“DemeRx”), a company focused on developing ibogaine for the treatment of opioid use disorder (OUD), will be presenting at Wonderland Miami Conference by Microdose on November 9th, 2021, The Evolution of Ibogaine Treatment.
DemeRx in joint partnership with atai Life Sciences received MHRA approval for DMX-1002 (Ibogaine) to commence a Phase 1/2a study as the first clinical trial in Opioid Use Disorder. The trial has begun enrollment and dosing of volunteers in the Phase 1 arm of the study.
DMX-1002 is an oral formulation of ibogaine, a naturally occurring psychedelic product isolated from a West African shrub. In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating opioid use disorder and shown potential to be a disease modifying treatment for this vulnerable patient population seeking to end their intractable cycle of drug dependence.
The Phase 1/2a trial is designed to assess safety, tolerability, pharmacokinetics, and efficacy, and the results will inform future studies in patients with opioid use disorder. We expect to obtain safety data from the phase 1 arm of this trial in early 2022.
“DemeRx looks forward to bringing important clinical data from carefully designed, controlled studies to the existing literature on ibogaine, a compound with substantial history,” said Deborah Mash, CEO and President of DemeRx. “We are hopeful that this early trial can begin to establish a safe and efficacious profile for Ibogaine, so that we can potentially offer a new option for patients seeking to break free from opioids who have far too few options.”
NOTES TO EDITORS
About DemeRx, Inc. & DMX-1002
DemeRx, Inc. is a Miami-based clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of opioid use disorder and other addictions. DemeRx’s mission is to advance the development of potential addictions treatments to prevent patient suffering, provide better treatment retention, and decrease illegal drug use.
DemeRx is developing DMX-1002 for the treatment of opioid use disorder. DMX-1002 is a GMP drug product manufactured for human use.
Contact Information
For DemeRx:
Company Contacts:
Deborah C Mash PhD
CEO & Founder, DemeRx Inc.
Phone: +1(305)753-2175
Email: [email protected] and [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102303
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
Cannabis
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE2 weeks ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis6 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis5 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan4 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey